CorMedix Inc. will announce Q1 2025 financial results on May 6 and host a conference call at 8:30am ET.
Quiver AI Summary
CorMedix Inc. has announced that it will release its financial results for the first quarter of 2025 on May 6, before the market opens, followed by a conference call at 8:30 AM ET to discuss the results. The company is focused on developing therapeutic products for serious health conditions, with its primary product being DefenCath®, which received FDA approval in November 2023. DefenCath was launched in both inpatient and outpatient settings in 2024, and CorMedix plans to begin clinical studies involving Total Parenteral Nutrition and pediatric patients in 2025, as well as explore additional uses for DefenCath as a catheter lock solution.
Potential Positives
- CorMedix will report its financial results for Q1 2025 on May 6, 2025, indicating transparent communication with investors.
- The company has successfully launched its lead product DefenCath® in both inpatient and outpatient settings, indicating effective commercialization efforts.
- CorMedix is expanding its research efforts by commencing clinical studies in Total Parenteral Nutrition and Pediatric populations, which could enhance product applicability and market potential.
- The approval of DefenCath® by the FDA on November 15, 2023, signifies regulatory validation of the product, which can boost investor confidence and market credibility.
Potential Negatives
- Details on financial performance prior to the earnings release might indicate ongoing financial struggles or uncertainty, which could negatively impact investor confidence.
- The announcement does not provide specific guidance for future earnings or product sales, which may raise concerns about the company's growth prospects.
- The need for additional clinical studies in various patient populations suggests that there may be challenges in establishing efficacy or market penetration for their lead product, DefenCath.
FAQ
When will CorMedix report its financial results?
CorMedix will report its financial results for Q1 2025 before the market opens on May 6, 2025.
What time is the CorMedix conference call?
The corporate update conference call will be hosted at 8:30 AM Eastern Time on May 6, 2025.
How can I access the CorMedix conference call?
You can access the conference call by calling 1-844-676-2922 for domestic or 1-412-634-6840 for international callers.
What is CorMedix's lead product?
CorMedix's lead product is DefenCath®, a therapeutic solution for preventing and treating life-threatening conditions.
When was DefenCath approved by the FDA?
DefenCath was approved by the FDA on November 15, 2023.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$CRMD Insider Trading Activity
$CRMD insiders have traded $CRMD stock on the open market 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $CRMD stock by insiders over the last 6 months:
- ELIZABETH HURLBURT (EVP) sold 140,027 shares for an estimated $1,565,669
- ERIN MISTRY (EVP, Chief Commercial Officer) purchased 1,500 shares for an estimated $14,984
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CRMD Hedge Fund Activity
We have seen 83 institutional investors add shares of $CRMD stock to their portfolio, and 36 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ROSALIND ADVISORS, INC. removed 1,475,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $11,947,500
- ELLIOTT INVESTMENT MANAGEMENT L.P. added 1,320,109 shares (+85.1%) to their portfolio in Q4 2024, for an estimated $10,692,882
- FIRST TURN MANAGEMENT, LLC added 1,021,421 shares (+inf%) to their portfolio in Q4 2024, for an estimated $8,273,510
- BLACKROCK, INC. added 911,603 shares (+24.9%) to their portfolio in Q4 2024, for an estimated $7,383,984
- VOYA INVESTMENT MANAGEMENT LLC removed 694,291 shares (-97.5%) from their portfolio in Q4 2024, for an estimated $5,623,757
- PALISADES INVESTMENT PARTNERS, LLC added 364,019 shares (+inf%) to their portfolio in Q4 2024, for an estimated $2,948,553
- UBS GROUP AG added 340,352 shares (+861.3%) to their portfolio in Q4 2024, for an estimated $2,756,851
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CRMD Analyst Ratings
Wall Street analysts have issued reports on $CRMD in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 12/19/2024
To track analyst ratings and price targets for $CRMD, check out Quiver Quantitative's $CRMD forecast page.
Full Release
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.
|
Tuesday, May 6
th
@ 8:30am ET
|
|
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Conference ID: | 10198548 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath ® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com .
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
[email protected]
(617) 430-7576
